Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang, Richard H. Wheeler, Randal S. Weber, David I. Rosenthal, Phuc Félix Nguyen‐Tan, William H. Westra, Christine H. Chung, Richard C. Jordan, Charles S. Lu, Harold L Kim, Rita Susan Axelrod, Craig L. Silverman, Kevin P. Redmond, Maura L. Gillison
New England Journal of Medicine · 2010 · 6,695 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Ang, K. K., Harris, J., Wheeler, R. H., Weber, R. S., Rosenthal, D. I., Nguyen‐Tan, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C. S., Kim, H. L., Axelrod, R. S., Silverman, C. L., Redmond, K. P., & Gillison, M. L. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine, 363(1), 24–35. https://doi.org/10.1056/nejmoa0912217
In text: (Ang et al., 2010)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown. METHODS: We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer. RESULTS: The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P=0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage. CONCLUSIONS: Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)
Related papers
- Cancer statistics, 20232023
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwide1999
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer2003
- Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures2013
- Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis2019
Metadata from OpenAlex (CC0). Citations are generated from the published record.